Mark Gilreath founded EndoChoice Inc. in 2008 and serves as its President & CEO. Under his leadership, the Company has been recognized 5 consecutive years by Inc. Magazine as one of the fastest growing companies in America. Gilreath led the company to its IPO on the New York Stock Exchange in June 2015.
Prior to EndoChoice, Mr. Gilreath served at Given Imaging (NASDAQ: GIVN) as President of The Americas and Chief Marketing Officer. During his eight years at Given Imaging, the company launched the PillCam Video Capsule and was transformed from a pre-revenue startup to a NASDAQ company exceeding $100 million in revenue.
Prior to joining Given Imaging, Mr. Gilreath served in a variety of management roles at Pentax Medical during seven years of rapid growth. He began his career serving in the U.S. military in Naval Intelligence during Operation Desert Storm.
Mr. Gilreath currently serves on the board of directors of EndoChoice Inc., the Metro Atlanta Chamber of Commerce, and the Medical Device Manufacturers Association (MDMA).
In 2013, Mr. Gilreath was selected as Business Person of the Year in Metro Atlanta. Gilreath holds a B.Sc. in Finance from Winthrop University and an MBA from the Fuqua School of Business at Duke University.
President & Chief Financial Officer
David N. Gill joined EndoChoice as its Chief Financial Officer in August 2014 and has worked in the medical device and life sciences industries for more than 20 years. Previously he served as the Chief Financial Officer of INC Research, a clinical research organization, from 2011 to 2013 after having served as a board member and its audit committee chairman from 2007 to 2010. Mr. Gill was the Chief Financial Officer of TransEnterix, a private surgical products company, from 2009 to 2011.
Prior to that, he was the Chief Financial Officer and Treasurer of NxStage Medical, Inc., a publicly-traded dialysis equipment company, from 2005 to 2006. From 2006 to 2009, Mr. Gill was retired and served as a director and audit committee chairman of two public life science companies, LeMaitre Vascular and Isotis Biologics, as well as several private life science companies.
Earlier in his career, Mr. Gill was the Senior Vice President and Chief Financial Officer of CTI Molecular Imaging, Inc., a publicly-traded medical imaging company, from 2002 to 2004, before its sale; was President, Chief Operating Officer, and Director, of Interland, Inc., a publicly-traded telecom-related company, from 2000 to 2001, before its sale; was Chief Operating Officer and Chief Financial Officer of Novoste Corporation, a publicly-traded medical device company, from 1996 to 2000; and served in executive leadership roles for Dornier Medical Systems, a private urologic equipment company, from 1990 to 1995, before its sale and was named President in 1992.
Mr. Gill holds a B.S. degree, cum laude, in Accounting from Wake Forest University and an MBA, with honors, from Emory University, and was formerly a certified public accountant. Mr. Gill currently serves on the board and as audit committee chairman of both Cempra Pharmaceuticals and Histogenics Corporation.
Yoram Ashery has 20 years experience in executing broad management and business responsibilities for the healthcare industry. He joined EndoChoice in April 2013. At EndoChoice, Mr. Ashery is responsible for growing the company's business across international markets by expanding the marketing, sales and service organizations, delivering the company's broad portfolio of products and services and unique customer experience while establishing its position as a leader in the international GI markets.
From 2007 to 2013, Mr. Ashery served as the CEO for Aposense Ltd. (TASE: APOS), a clinical stage biopharma and global leader in the development of small molecular drugs that target apoptosis (programmed cell death) for molecular imaging and therapy. As CEO, Mr. Ashery led the company's reorganization from a research and discovery group to a market driven, state-of-the-art drug development firm. Under his leadership, the company more than doubled its drug pipeline, entered multiple partnerships with big pharma and commercial partners and went public on the Tel-Aviv Stock Exchange.
From 2000 to 2006, Mr. Ashery served as Vice President, Business Development for Given Imaging and member of its executive management, with a focus on strategic and international expansion. Before joining Given Imaging, Mr. Ashery was a partner with Zellermayer, Pelossof & Co., one of Israel's premier corporate law firms, where he practiced and led corporate finance, M&A and licensing transactions in the medical technology sector.
Mr. Ashery holds a LL.B (Law) and B.A. Economics cum laude from Tel Aviv University, and serves on the governing board of the Israeli Public Companies Association, as head of the organization’s life-sciences section.
Will Parks has worked in the field of GI devices since 1992. He co-founded EndoChoice with Mark Gilreath in late 2007. At EndoChoice, Mr. Parks is responsible for creating and managing strategic business partnerships around the world, evaluation of new product inventions and identification of portfolio enhancing companies.
Prior to EndoChoice, Mr. Parks successfully led Champion Cart Corporation, which he also co-founded with Mr. Gilreath in 1993. Champion Cart, which grew more than 30% annually in revenues was eventually merged into EndoChoice in October 2007.
From 1992 to 2002, Mr. Parks worked at PENTAX Medical as a Manufacturer's Distributor focused on GI endoscopy video equipment, therapeutic devices, and repair services. In this role, Mr. Parks won several awards for leading two regions from declining sales to significant gains.
Mr. Parks holds a B.Sc. in Marketing and an MBA from Winthrop University.
Gregg Costantino has worked in the field of GI devices since 1995 in sales leadership positions within service and device organizations. He joined EndoChoice in early 2008 and is responsible for driving revenues via the U.S. sales organization. He also leads the sales training and operations organization plus national and corporate accounts.
Prior to EndoChoice, Mr. Costantino served as Manager of Market Development for Boston Scientific Endoscopy. From 2004 to 2008, Mr. Costantino held a variety of leadership positions in Sales, Training, and Marketing. During that time, he won a number of sales awards, including the President's Club award in 2005 and 2006, which honors the top performers within the sales organization.
From 1995 to 2004, Mr. Costantino held a variety of positions with Factory Authorized Medical Scope Repair, including Territory Manager, Eastern Area Sales Manager, Director of Sales and Operations and Vice President of Sales.
Mr. Costantino holds a B.A. from Harvard University.
Andy Lyness joined EndoChoice in 2013. At EndoChoice, Mr. Lyness serves as the Company’s global HR leader, and is responsible for the design and development of global human resources strategies and the delivery of programs and services that drive the company’s objectives, support the diverse workforce and foster our unique culture. Mr. Lyness also serves as the Company’s Chief Compliance Officer.
Prior to joining EndoChoice, Mr. Lyness practiced law at King & Spalding, where hispractice focused on advising clients on a range of corporate compliance and governance matters. He also represented clients through a variety of criminal and civil government investigations, principally in the healthcare and securities areas.
Mr. Lyness earned his bachelor’s degree from the University of Georgia and his JD from Georgia State University. Andy is a member of the American Health Lawyers Association and the Health Law section of the Georgia Bar.
GB Pratt has worked in the field of GI services and healthcare IT since 1996 in sales and operational leadership roles. He joined EndoChoice in 2008 and is responsible for Technology Enabled Services which includes diagnostics, scope services and customer care. All three service units have similar operational demands and frequent, almost daily, interactions with our customers. Mr. Pratt ensures the team provides world-class support in our mission to serve the GI caregiver.
Prior to EndoChoice, Mr. Pratt served in a variety of management positions within the healthcare IT space. Mr. Pratt was the co-founder and CEO of VLink, a healthcare integration platform that linked hospitals with physician electronic medical records (EMR’s). VLink was sold in 2008 to Portico Systems, a partner company of Safeguard Scientifics (NYSE: SFE). From 2002 to 2006 he held several roles, including Vice President of Sales for eko systems, a provider of hospital-based EMR’s for the perioperative space.
From 1996 to 2002, Mr. Pratt held several positions with Factory Authorized Medical Scope Repair including Territory Manager, Regional Manager and Eastern Area Sales Manager.
Mr. Pratt holds a B.Sc. in Marketing from Pennsylvania State University.
Nigel Wilkinson has worked in Quality Assurance and Regulatory Affairs in
the Medical Device industry for more than 25 years, with experience in
Sports Medicine, Orthopaedics and Ophthalmic specialties. He joined
EndoChoice in 2013, and is responsible for ensuring our activities comply with
relevant laws, rules and regulations, wherever we do business. This
includes Quality Management Systems, Good Manufacturing Practices,
obtaining approvals/registrations for product in global markets, and
post-market surveillance programs.
Prior to joining EndoChoice, Mr. Wilkinson served many years in a variety of
roles at Smith & Nephew Inc., most recently as Sr. Vice President, Quality
Assurance where he was responsible for global Quality programs for
Advanced Surgical Devices.
From 1998 to 2011, he was Sr. Vice President, RA/QA at Smith & Nephew's
Endoscopy Division, responsible for global QA, regulatory compliance and
regulatory submissions for a Sports Medicine business, covering diverse
technologies including Medical Video, Endoscopy, single use and
reusable instruments, implants, and other electrical capital products.
From 1995 to 1998, he fulfilled a Corporate role at Smith & Nephew,
serving as Director of Regulatory Compliance. From 1989
to 2005, Mr. Wilkinson served as Quality Director at Ioptex Inc. Prior to 1989, he had
various roles in medical industries.
Mr. Wilkinson was raised and educated in the UK, and holds a BSc from the
University of London, with dual majors in Microbiology and Genetics.
Brit Young joined EndoChoice in early 2008 as General Counsel & Director of Business Development and leads the company’s global legal, intellectual property, and M&A activities, as well as supports new business development efforts, including strategic partnerships and licensing opportunities.
Mr. Young was first introduced to EndoChoice in 2007 while in the corporate transactions group at Womble Carlyle Sandridge & Rice, a leading corporate law firm. He served as EndoChoice’s first outside counsel and worked with Mark Gilreath and Will Parks to incorporate the company and secure its initial rounds of financing. During his tenure in private practice, Mr. Young worked with a wide variety of high-growth companies helping them manage complex transactions such as mergers, acquisitions, partnerships and venture financings.
Mr. Young earned his bachelor’s degree in finance, MBA and JD from the University of Florida.
US: 888.682.ENDO (3636)Intl: +49 (0) 4101 5173-0